Clinical trials: Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)
- Condition Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)
- Funder type Industry (pharma, biotech, devices)
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie